[1] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA: a cancer journal for clinicians. 2017;67:7-30.
[2] Diaz-Padilla I, Romero N, Amir E, Matias-Guiu X, Vilar E, Muggia F, et al. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Critical reviews in oncology/hematology. 2013;88:154-67.
[3] Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387:1094-108.
[4] Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ. Contemporary management of endometrial cancer. Lancet. 2012;379:1352-60.
[5] Khorkova O, Hsiao J, Wahlestedt C. Basic biology and therapeutic implications of lncRNA. Advanced drug delivery reviews. 2015;87:15-24.
[6] Jarroux J, Morillon A, Pinskaya M. History, Discovery, and Classification of lncRNAs. Advances in experimental medicine and biology. 2017;1008:1-46.
[7] Chi Y, Wang D, Wang J, Yu W, Yang J. Long Non-Coding RNA in the Pathogenesis of Cancers. Cells. 2019;8.
[8] Kreutzer FP, Fiedler J, Thum T. Non-coding RNAs: key players in cardiac disease. The Journal of physiology. 2019.
[9] Yao RW, Wang Y, Chen LL. Cellular functions of long noncoding RNAs. Nature cell biology. 2019;21:542-51.
[10] Uchida S, Dimmeler S. Long noncoding RNAs in cardiovascular diseases. Circulation research. 2015;116:737-50.
[11] Schmitt AM, Chang HY. Long Noncoding RNAs in Cancer Pathways. Cancer cell. 2016;29:452-63.
[12] Bao G, Huang J, Pan W, Li X, Zhou T. Long noncoding RNA CERS6-AS1 functions as a malignancy promoter in breast cancer by binding to IGF2BP3 to enhance the stability of CERS6 mRNA. Cancer medicine. 2019.
[13] Yan Z, Zhang W, Xiong Y, Wang Y, Li Z. Long noncoding RNA FLVCR1-AS1 aggravates biological behaviors of glioma cells via targeting miR-4731-5p/E2F2 axis. Biochemical and biophysical research communications. 2019.
[14] He J, Yu J. Long noncoding RNA FAM83A-AS1 facilitates hepatocellular carcinoma progression by binding with NOP58 to enhance the mRNA stability of FAM83A. Bioscience reports. 2019.
[15] Chen BJ, Byrne FL, Takenaka K, Modesitt SC, Olzomer EM, Mills JD, et al. Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer. Gynecologic oncology. 2017;147:654-62.
[16] Sun KX, Wu DD, Chen S, Zhao Y, Zong ZH. LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway. Apoptosis : an international journal on programmed cell death. 2017;22:1543-52.
[17] Chen S, Wang LL, Sun KX, Liu Y, Guan X, Zong ZH, et al. LncRNA TDRG1 enhances tumorigenicity in endometrial carcinoma by binding and targeting VEGF-A protein. Biochimica et biophysica acta Molecular basis of disease. 2018;1864:3013-21.
[18] Yang X, Wang CC, Lee WYW, Trovik J, Chung TKH, Kwong J. Long non-coding RNA HAND2-AS1 inhibits invasion and metastasis in endometrioid endometrial carcinoma through inactivating neuromedin U. Cancer letters. 2018;413:23-34.
[19] Reymond A, Friedli M, Henrichsen CN, Chapot F, Deutsch S, Ucla C, et al. From PREDs and open reading frames to cDNA isolation: revisiting the human chromosome 21 transcription map. Genomics. 2001;78:46-54.
[20] Chen Y, Mao ZD, Shi YJ, Qian Y, Liu ZG, Yin XW, et al. Comprehensive analysis of miRNA-mRNA-lncRNA networks in severe asthma. Epigenomics. 2019;11:115-31.
[21] Yu J, Jiang L, Gao Y, Sun Q, Liu B, Hu Y, et al. LncRNA CCAT1 negatively regulates miR-181a-5p to promote endometrial carcinoma cell proliferation and migration. Experimental and therapeutic medicine. 2019;17:4259-66.
[22] Sun H, Yan L, Tu R, Zhang Y, Ma L, Tang W, et al. Expression Profiles of Endometrial Carcinoma by Integrative Analysis of TCGA Data. Gynecologic and obstetric investigation. 2017;82:30-8.
[23] Li Y, Syed J, Sugiyama H. RNA-DNA Triplex Formation by Long Noncoding RNAs. Cell chemical biology. 2016;23:1325-33.
[24] Li BL, Wan XP. The role of lncRNAs in the development of endometrial carcinoma. Oncology letters. 2018;16:3424-9.
[25] Smolle MA, Bullock MD, Ling H, Pichler M, Haybaeck J. Long Non-Coding RNAs in Endometrial Carcinoma. International journal of molecular sciences. 2015;16:26463-72.
[26] Takenaka K, Chen BJ, Modesitt SC, Byrne FL, Hoehn KL, Janitz M. The emerging role of long non-coding RNAs in endometrial cancer. Cancer genetics. 2016;209:445-55.
[27] Wang Y, Li XP, Yin JY, Zhang Y, He H, Qian CY, et al. Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response. Clinical and experimental pharmacology & physiology. 2014;41:408-15.
[28] Shin YJ, Kim MS, Kim MS, Lee J, Kang M, Jeong JH. High-mobility group box 2 (HMGB2) modulates radioresponse and is downregulated by p53 in colorectal cancer cell. Cancer biology & therapy. 2013;14:213-21.
[29] Cai X, Ding H, Liu Y, Pan G, Li Q, Yang Z, et al. Expression of HMGB2 indicates worse survival of patients and is required for the maintenance of Warburg effect in pancreatic cancer. Acta biochimica et biophysica Sinica. 2017;49:119-27.
[30] Fu D, Li J, Wei J, Zhang Z, Luo Y, Tan H, et al. HMGB2 is associated with malignancy and regulates Warburg effect by targeting LDHB and FBP1 in breast cancer. Cell communication and signaling : CCS. 2018;16:8.
[31] Syed N, Chavan S, Sahasrabuddhe NA, Renuse S, Sathe G, Nanjappa V, et al. Silencing of high-mobility group box 2 (HMGB2) modulates cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell carcinoma. Proteomics. 2015;15:383-93.
[32] Zhang P, Lu Y, Gao S. High-mobility group box 2 promoted proliferation of cervical cancer cells by activating AKT signaling pathway. Journal of cellular biochemistry. 2019;120:17345-53.
[33] Cui G, Cai F, Ding Z, Gao L. HMGB2 promotes the malignancy of human gastric cancer and indicates poor survival outcome. Human pathology. 2019;84:133-41.
[34] Han Q, Xu L, Lin W, Yao X, Jiang M, Zhou R, et al. Long noncoding RNA CRCMSL suppresses tumor invasive and metastasis in colorectal carcinoma through nucleocytoplasmic shuttling of HMGB2. Oncogene. 2019;38:3019-32.
[35] Xu CH, Xiao LM, Liu Y, Chen LK, Zheng SY, Zeng EM, et al. The lncRNA HOXA11-AS promotes glioma cell growth and metastasis by targeting miR-130a-5p/HMGB2. European review for medical and pharmacological sciences. 2019;23:241-52.
[36] Dykes IM, Emanueli C. Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA. Genomics, proteomics & bioinformatics. 2017;15:177-86.